REPLIXCEL

Highly efficient new generation synthetic RNA-replicon based vaccine

Coordinatore	THE UNIVERSITY OF MANCHESTER    more  Organization address address: OXFORD ROAD city: MANCHESTER postcode: M13 9PL contact info Titolo: Ms. Nome: Liz Cognome: Fay Email: send email Telefono: +44 161 2757114 Fax: +44 161 2752445
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	2˙591˙172 €
EC contributo	2˙591˙172 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2009-IAPP
Funding Scheme	MC-IAPP
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-04-01   -   2014-03-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	THE UNIVERSITY OF MANCHESTER  Organization address address: OXFORD ROAD city: MANCHESTER postcode: M13 9PL contact info Titolo: Ms. Nome: Liz Cognome: Fay Email: send email Telefono: +44 161 2757114 Fax: +44 161 2752445	UK (MANCHESTER)	coordinator	799˙522.00
2	Medipol SA  Organization address address: "Parc Scientifique EPEL, PSE-B 1" city: Lausanne postcode: 1015 contact info Titolo: Dr. Nome: Carsten Cognome: Laue Email: send email Telefono: +41 21 6939031 Fax: +41 21 6939032	CH (Lausanne)	participant	748˙840.00
3	EIDGENOESSISCHES DEPARTEMENT FUER WIRTSCHAFT, BILDUNG UND FORSCHUNG  Organization address address: Bundeshaus Ost city: BERN postcode: 3003 contact info Titolo: Dr. Nome: Kenneth Charles Cognome: Mccullough Email: send email Telefono: +41 31 848 9262 Fax: +41 31 848 9222	CH (BERN)	participant	739˙085.00
4	EMC MICROCOLLECTIONS GMBH  Organization address address: Sindelfinger Str. 3 city: TUEBINGEN postcode: 72070 contact info Titolo: Dr. Nome: Renate Cognome: Spohn Email: send email Telefono: +49 7070 407424 Fax: +49 7071 407422	DE (TUEBINGEN)	participant	303˙725.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The project seeks to create a novel, efficacious vaccine against influenza virus; a new type of synthetic vaccine readily adaptable to meet whichever influenza virus subtype may arise. A new generation of RNA-replicon technology will be employed combined with nanoparticles and innovative adjuvants for targeting of dendritic cells and efficient antigen expression. The consortium comprises two SMEs and two academic institutions each having unique and patented expertise such as replicon technology, nanoparticle technology, adjuvant chemistry, and surface modification chemistry to attach targeting moieties. As a highly interdisciplinary project, extensive exchange of knowledge between the project partners will be required in particular between product focused SMEs (nanoparticles, adjuvants) and technology excellence of academic institutions (replicon technology, surface modification chemistry).'